Menu Search
Equities

Ocular Therapeutix Inc

OCUL:NMQ

Ocular Therapeutix Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.60
  • Today's Change-0.36 / -3.28%
  • Shares traded627.61k
  • 1 Year change+403.56%
  • Beta1.2204
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Ocular Therapeutix Inc had net income fall 13.65% from a loss of 71.04m to a larger loss of 80.74m despite a 13.49% increase in revenues from 51.49m to 58.44m.
Gross margin90.84%
Net profit margin-226.46%
Operating margin-209.88%
Return on assets-43.26%
Return on equity-72.67%
Return on investment-47.93%
More ▼

Cash flow in USDView more

In 2023, Ocular Therapeutix Inc increased its cash reserves by 89.86%, or 93.51m. Cash Flow from Financing totalled 169.83m or 290.59% of revenues. In addition the company used 70.23m for operations while cash used for investing totalled 6.09m.
Cash flow per share-1.16
Price/Cash flow per share--
Book value per share2.43
Tangible book value per share2.43
More ▼

Balance sheet in USDView more

Ocular Therapeutix Inc appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio16.64
Quick ratio16.55
Total debt/total equity0.1777
Total debt/total capital0.1509
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.